Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

(NASDAQ:SNY) Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Symbol: SNY
9 days ago

Verkkokauppa.com Oyj has completed the sale of its consumer financing business to Walley

(VERK) Verkkokauppa.com Oyj has completed the sale of its consumer financing business to Walley

Symbol: VERK
9 days ago

Spring Valley Acquisition Corp. III Announces Pricing of $200 Million Initial Public Offering

(NASDAQ:SVACU) DALLAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Spring Valley Acquisition Corp. III (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, ...

Symbol: SVACU
9 days ago

Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

(NASDAQ:BRKR) BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 milli...

Symbol: BRKR
9 days ago

Strathcona Resources Ltd. Provides Update on Form of $2.1 Billion Special Distribution

(NYSE:STR) CALGARY, AB, Sept. 3, 2025 /PRNewswire/ - Strathcona Resources Ltd. ("Strathcona") announced today the anticipated form of the previously disclosed $2.142 billion special distribution (t...

Symbol: STR
9 days ago

Customers Bancorp, Inc. Announces Pricing of Voting Common Stock Offering

(NYSE:CUBI) WEST READING, Pa.--(BUSINESS WIRE)---- $CUBI #Banking--Customers Bancorp, Inc. (NYSE: CUBI) (“Customers” or the “Company”), a holding company that operates through its wholly owned bank...

Symbol: CUBI
9 days ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

(NASDAQ:MESO) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it h...

Symbol: MESO
9 days ago